JP2001509512A5 - - Google Patents

Download PDF

Info

Publication number
JP2001509512A5
JP2001509512A5 JP2000502063A JP2000502063A JP2001509512A5 JP 2001509512 A5 JP2001509512 A5 JP 2001509512A5 JP 2000502063 A JP2000502063 A JP 2000502063A JP 2000502063 A JP2000502063 A JP 2000502063A JP 2001509512 A5 JP2001509512 A5 JP 2001509512A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nucleotide
independently represent
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP4950380B2 (ja
JP2001509512A (ja
Filing date
Publication date
Priority claimed from SE9702680A external-priority patent/SE9702680D0/xx
Application filed filed Critical
Publication of JP2001509512A publication Critical patent/JP2001509512A/ja
Publication of JP2001509512A5 publication Critical patent/JP2001509512A5/ja
Application granted granted Critical
Publication of JP4950380B2 publication Critical patent/JP4950380B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000502063A 1997-07-11 1998-06-29 新規な製剤 Expired - Lifetime JP4950380B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702680-1 1997-07-11
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (3)

Publication Number Publication Date
JP2001509512A JP2001509512A (ja) 2001-07-24
JP2001509512A5 true JP2001509512A5 (cg-RX-API-DMAC10.html) 2006-01-05
JP4950380B2 JP4950380B2 (ja) 2012-06-13

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000502063A Expired - Lifetime JP4950380B2 (ja) 1997-07-11 1998-06-29 新規な製剤

Country Status (35)

Country Link
US (1) US6130208A (cg-RX-API-DMAC10.html)
EP (1) EP1000079B1 (cg-RX-API-DMAC10.html)
JP (1) JP4950380B2 (cg-RX-API-DMAC10.html)
KR (1) KR100786654B1 (cg-RX-API-DMAC10.html)
CN (2) CN1864696A (cg-RX-API-DMAC10.html)
AR (1) AR013157A1 (cg-RX-API-DMAC10.html)
AT (1) ATE340801T1 (cg-RX-API-DMAC10.html)
AU (1) AU8362598A (cg-RX-API-DMAC10.html)
BR (1) BR9810703A (cg-RX-API-DMAC10.html)
CA (1) CA2295628C (cg-RX-API-DMAC10.html)
CY (1) CY1105805T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298110B6 (cg-RX-API-DMAC10.html)
DE (1) DE69836023T2 (cg-RX-API-DMAC10.html)
DK (1) DK1000079T3 (cg-RX-API-DMAC10.html)
EE (1) EE04119B1 (cg-RX-API-DMAC10.html)
ES (1) ES2273425T3 (cg-RX-API-DMAC10.html)
HU (1) HU226489B1 (cg-RX-API-DMAC10.html)
ID (1) ID24716A (cg-RX-API-DMAC10.html)
IL (2) IL133868A0 (cg-RX-API-DMAC10.html)
IS (1) IS2439B (cg-RX-API-DMAC10.html)
MY (1) MY116421A (cg-RX-API-DMAC10.html)
NO (1) NO329918B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ502073A (cg-RX-API-DMAC10.html)
PL (1) PL192768B1 (cg-RX-API-DMAC10.html)
PT (1) PT1000079E (cg-RX-API-DMAC10.html)
RU (1) RU2216330C2 (cg-RX-API-DMAC10.html)
SA (1) SA98190328B1 (cg-RX-API-DMAC10.html)
SE (1) SE9702680D0 (cg-RX-API-DMAC10.html)
SI (1) SI1000079T1 (cg-RX-API-DMAC10.html)
SK (1) SK285766B6 (cg-RX-API-DMAC10.html)
TR (1) TR200000006T2 (cg-RX-API-DMAC10.html)
TW (1) TW585764B (cg-RX-API-DMAC10.html)
UA (1) UA65576C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999002542A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA985669B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 3−(ビアリールオキシ)プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
WO2012079035A1 (en) * 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (cg-RX-API-DMAC10.html) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社 ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Similar Documents

Publication Publication Date Title
FI104176B (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
JP3723227B2 (ja) ジ(ウリジン5’)−テトラホスフェート及びその塩の大規模生産のための方法
RU2292894C2 (ru) Новый способ ингибирования роста вирусов и/или вирулицидный способ и новый аналог пиразиннуклеотида или пиразиннуклеозида
ES2907874T3 (es) Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
CN104640444B (zh) 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
JP3083156B2 (ja) N−アルキル−2−置換atp類似体
EP0785208B1 (en) Phosphonate nucleotide compounds
JP2018517709A (ja) 選択的な無溶媒リン酸化
Wang et al. Synthesis of AZT 5 ‘-Triphosphate mimics and their inhibitory effects on HIV-1 reverse transcriptase
HUT73659A (en) New antiviral nucleoside derivatives
WO2001060834A1 (en) Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both
JP2001522369A (ja) 抗ウイルスピリミジンヌクレオシド類似体
JPH05247070A (ja) プリンとピリミジンの新規な不飽和非環式ホスホネート誘導体類
JP2007269798A (ja) B型肝炎の治療のためのβ−L−2’−デオキシ−ヌクレオシド
CA2890676A1 (en) Phosphonucleosides useful in the treatment of viral disorders
HU217772B (hu) 3'-Helyettesített nukleozidszármazékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
US7091334B2 (en) Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof
EP4516798A1 (en) Nucleoside drug for treating or preventing coronavirus infection, and use thereof
CN106661075A (zh) 二磷酸和三磷酸前体药物
RU2000103216A (ru) Новая композиция
JP2001509512A (ja) 新規な製剤
HU204843B (en) Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
JPS6411637B2 (cg-RX-API-DMAC10.html)
US6548658B2 (en) Di-(uridine 5′)-tetraphosphate and salts thereof
WO1989005817A1 (en) Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds